HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor

Abstract : Small-molecule kinase inhibitors (SMKIs) have been widely used in the treatment of a variety of cancers due to their clinically demonstrated efficacy. However, the use of some SMKIs, such as sorafenib (SO), has been plagued by their cardiotoxicity that has been frequently observed in treated patients. Herein we report that the encapsulation of SO by a synthetic receptor cucurbit[7]uril (CB[7]) alleviated the inherent cardiotoxicity of SO, as demonstrated in an in vivo zebrafish model. Moreover, the anti-cancer activity of SO was well preserved, upon its encapsulation by CB[7], as demonstrated by both in vitro and in vivo cancer/angiogenesis models. This discovery may provide new insights into a novel supramolecular formulation of SMKIs for the management of their side-effects.
Document type :
Journal articles
Complete list of metadata

Contributor : Marlene Delhaye Connect in order to contact the contributor
Submitted on : Monday, April 23, 2018 - 2:41:15 PM
Last modification on : Wednesday, March 23, 2022 - 3:50:49 PM




Xue Yang, Qiaoxian Huang, David Bardelang, Chunming Wang, Simon M. Y. Lee, et al.. Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor. Organic and Biomolecular Chemistry, Royal Society of Chemistry, 2017, 15 (38), pp.8046--8053. ⟨10.1039/c7ob01505d⟩. ⟨hal-01774176⟩



Record views